Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.79 |
| ▸ | HTR2C | P28335 | 9/20 | 0.76 |
| ▸ | QDPR | P09417 | 3/20 | 0.56 |
| ▸ | HTR6 | P50406 | 2/20 | 0.55 |
| ▸ | HTR7 | P34969 | 1/20 | 0.55 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | KHK | P50053 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4793458 | 0.98 | HTR2C (0.79) | SIGMAR1HTR2CQDPRHTR6HTR7 | |
| SCHEMBL3899585 | 0.89 | SIGMAR1 (0.92) | SIGMAR1HTR2CQDPRHTR6HTR7 | |
| SCHEMBL415545 | 0.89 | SIGMAR1 (1.00) | SIGMAR1HTR2CQDPRHTR6HTR7 | |
| Bromide SCHEMBL11385943 | 0.87 | SIGMAR1 (0.96) | SIGMAR1HTR2CQDPRHTR6HTR7 | |
| Hydrochloric Acid SCHEMBL446973 | 0.87 | HTR2C (1.00) | SIGMAR1HTR2CQDPRHTR6HTR7 | |
| Hydrochloric Acid SCHEMBL3676212 | 0.85 | SIGMAR1 (0.92) | SIGMAR1HTR2CQDPRHTR6HTR7 | |
| SCHEMBL11204336 | 0.82 | SIGMAR1 (0.67) | SIGMAR1HTR2CQDPRHTR6HTR7 | |
| SCHEMBL29914651 | 0.81 | HTR2C (0.66) | SIGMAR1HTR2CQDPR | |
| SCHEMBL21228136 | 0.81 | HTR2C (0.66) | SIGMAR1HTR2CQDPR | |
| SCHEMBL4510248 | 0.81 | HTR2C (1.00) | SIGMAR1HTR2CQDPRHTR6HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1996550-A2 | CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES | Novartis AG (CH) | 2008-12-03 | — | — | EP | claimed |
| US-20080255149-A1 | Carboxyamine Compounds and Methods of Use Thereof | NOVARTIS AG | 2008-10-16 | — | — | US | claimed |
| WO-2007038459-A2 | CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES | NOVARTIS AG (CH) | 2007-04-05 | — | — | WO | claimed |
| EP-1996550-A2 | CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES | Novartis AG (CH) | 2008-12-03 | — | — | EP | disclosed |
| US-20080255149-A1 | Carboxyamine Compounds and Methods of Use Thereof | NOVARTIS AG | 2008-10-16 | — | — | US | disclosed |
| US-20080255149-A1 | Carboxyamine Compounds and Methods of Use Thereof | NOVARTIS AG | 2008-10-16 | — | — | US | disclosed |
| US-20080255149-A1 | Carboxyamine Compounds and Methods of Use Thereof | NOVARTIS AG | 2008-10-16 | — | — | US | disclosed |
| WO-2007038459-A2 | CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES | NOVARTIS AG (CH) | 2007-04-05 | — | — | WO | disclosed |
| WO-2007038459-A2 | CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES | NOVARTIS AG (CH) | 2007-04-05 | — | — | WO | disclosed |
| US-5712285-A | Pyrrolo-pyridine derivatives | MERCK, SHARP & DOHME, LTD. (GB) | 1998-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255149-A1 | Carboxyamine Compounds and Methods of Use Thereof | HNMT, HDAC5, HDAC4 | SIGMAR1 2655/4885HTR2C 424/4885QDPR 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.